Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

298.70 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Mark To Market
I thought that I would have a look at my own financial performance in 2021. In preview, I did alright, but not as well as the market. Let's take a look at what my portfolio held and how well it did. 
Via Talk Markets
United Therapeutics Corporation to Webcast Executive Fireside Chat Conversation With J.P. Morgan Analyst
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2022
From United Therapeutics Corporation
Via Business Wire
Liquidia's Inhaled Treprostinil Powder Scores Tentative FDA Approval For PAH
The FDA has granted tentative approval to Liquidia Corporation's (NASDAQ: LQDA) Yutrepia (treprostinil) inhalation powder for pulmonary arterial... 
Via Benzinga
Exposures Product Safety
United Therapeutics Corporation (UTHR) Q3 2021 Earnings Call Transcript
UTHR earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Exposures Pension
Recap: United Therapeutics Q3 Earnings
United Therapeutics (NASDAQ:UTHR) reported its Q3 earnings results on Wednesday, November 3, 2021 at 08:00 AM. Here's what investors need to know about the announcement... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Why Shares of MannKind Corporation Are Falling This Morning
Investors are hyperventilating after a delay for its inhaled medicine. 
Via The Motley Fool
FDA Declines MannKind - United Therapeutics' Formulated Treprostinil For Lung Disease
The FDA has issued a complete response to United Therapeutics Corporation (NASDAQ: UTHR) regarding the marketing application for Tyvaso DPI for pulmonary... 
Via Benzinga
Exposures Product Safety
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer?
A biotech working in lung and blood diseases, as well as cancer, could be acquired. 
Via Investor's Business Daily
United Therapeutics-MannKind's Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients
United Therapeutics Corporation (NASDAQ: UTHR) has presented new clinical data from the BREEZE study evaluating Tyvaso DPI (treprostinil) in patients with pulmonary... 
Via Benzinga
Innovators in Pharma Sectors See Potential, Promise in Providing Improved Treatments
Via FinancialNewsMedia
Why United Therapeutics Blasted 14% Higher Today
Every one of the company's products booked a revenue gain in Q2. 
Via The Motley Fool
United Therapeutics Corporation (UTHR) Q2 2021 Earnings Call Transcript
UTHR earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
88 Biggest Movers From Yesterday
Gainers BeyondSpring Inc. (NASDAQ: BYSI) shares climbed 176% to close at $26.58 on Wednesday in reaction to topline data from DUBLIN-3 Phase 3 trial evaluating plinabulin in... 
Via Benzinga
United Therapeutics: Q2 Earnings Insights
Shares of United Therapeutics (NASDAQ:UTHR) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share increased 11.14% over the past... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Mostly lower Ahead Of General Motors Earnings
Pre-open movers U.S. stock futures traded mostly lower in early pre-market trade after the Dow Jones surged around 280 points in the previous session. Investors are awaiting... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19 Product Safety
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter. • Vericel (NASDAQ:VCEL) is expected to... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2021
Upgrades CL King upgraded the previous rating for Compass Minerals International Inc (NYSE: 
Via Benzinga
MannKind - United Therapeutics' Formulated Treprostinil Under FDA Review For Pulmonary Hypertension
MannKind Corporation (NASDAQ: MNKD) and United Therapeutics Corporation (NASDAQ: UTHR) have announced that the FDA has accepted for review the marketing... 
Via Benzinga
Exposures Product Safety
Price Over Earnings Overview: United Therapeutics
Looking into the current session, United Therapeutics Inc. (NASDAQ:UTHR) is trading at $193.48, after a 2.35% decrease. Over the past month, the stock fell by 3.61... 
Via Benzinga
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company... 
Via Benzinga
10 Biggest Price Target Changes For Thursday
Rosenblatt lifted the price target on Qorvo Inc (NASDAQ: QRVO) from $175 to $200. Qorvo shares rose 0.8% to $184.01 in pre-market trading. Needham boosted HubSpot Inc (NASDAQ:... 
Via Benzinga
United Therapeutics Corp (UTHR) Q1 2021 Earnings Call Transcript
UTHR earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.